Phase 2 N=232 UW Withdraw From Tobacco Study
Tobacco Dependence
Primary: Change in Total Score on Wisconsin Smoking Withdrawal Scale2 Long (WSWS2-L) — 2.64; 2.36; 2.29; 2.69 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 Treatment for Nicotine Addiction in Women
Nicotine Dependence
Primary: Withdrawal Symptoms (MNWS Score) — 13.33; 9.40; 11.95; 13.29 score on a scale — p=0.18
Phase 4 N=226 Stress Neuroadaptation in Tobacco Dependence
Nicotine Dependence
Primary: Overall Stressor Reactivity — 25.1; 22.5; 32.3; 16.9 microvolts
Phase 3 N=120 S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence
Tobacco Dependence
Primary: 7-day Point Prevalence Smoking Abstinence at End of Treatment (Week 8) — 7; 5; 7 participants — p=0.615
N/A N=34 Youth Smoking Cessation: Therapy +/- "The Patch"
Smoking
Primary: Acceptance of Nicotine Replacement Therapy — 26 participants
Phase 2 N=46 Neural Substrates in Nicotine Withdrawal
Tobacco Use Disorder
Primary: Measure of Brain Activity: Blood Oxygen Level Dependent (BOLD) fMRI Signal Change During the "N-back" Working Memory Task (Brain Region: Right Dorsolateral Prefrontal…
N/A N=224 Treating Tobacco Dependence in Inpatient Psychiatry - 1
Tobacco Use Cessation · Tobacco Use Disorder
Primary: 7 Day Point Prevalence of Cigarette Abstinence — 3; 14; 6; 14 Participants — p=0.018
N/A N=109 Tobacco Dependence Treatment for Asian Americans
Tobacco Dependence
Primary: 12-month Abstinence — 21; 6 Participants — p=<0.01
Phase 4 N=47 Nicotine Replacement Therapy in the Intensive Care Unit
Delirium · Psychomotor Agitation · Substance Withdrawal Syndrome
Primary: 30-day Mortality — 9.5; 7.7 percentage of patients
N/A N=40 QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt
Smoking · Smoking Cessation · Craving
Primary: Questionnaire on Smoking Urges Administered Daily Pre TMS to Measure Craving — 16; 12 units on a scale
Phase 1 N=15 Brain Imaging in Tobacco Smokers During a Quit Attempt
Tobacco Use Disorder · Tobacco Smoking
Primary: Distribution Volume (VT) as Determined by [18F]-ASEM PET Scan — 22.640; 21.588; 22.226; 17.431 mL/cm^3
Phase 2 N=114 N-acetylcysteine for Tobacco Use Disorder
Nicotine Dependence · Smoking
Primary: Number of Participants With Biochemically-verified Abstinence From Smoking on Days 1-3 of the Protocol. — 8; 6 Participants
Phase 4 N=127 Nicotine Patch for Marijuana Withdrawal
Marijuana Dependence
Primary: Profile of Mood Scale Total Negative Affect (Tension + Depression + Anger) — 8.52; 8.096; 5.14; 4.615 units on a scale
Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
N/A N=76 Varenicline for the Treatment of Smokeless Tobacco
Nicotine Dependence
Primary: 7-day Point Prevalence All Tobacco Abstinence — 21; 16 participants — p=0.126
Phase 2 N=118 St. John's Wort for Tobacco Cessation
Smoking · Nicotine Dependence
Primary: Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco — 7; 8; 6 participants — p=0.52
N/A N=78 Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC): Reducing Tobacco Use Among Opioid Addicted Women
Smoking Cessation
Primary: Change in the Number of Cigarettes Smoked Per Day — 0; 0 cigarettes per day
Phase 2 N=34 Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal
Impulse Control Disorders
Primary: Safety and Tolerability of SXC-2023. — 0; 0; 0; 0 Events
N/A N=104 Accelerated iTBS in Smoking Cessation
Nicotine Dependence · Smoking Cessation
Primary: Self-reported Nicotine Consumption — 27.55; 26.83; 30.00 cigarettes/day
N/A N=433 Take a Break (TAB): mHealth-assisted Skills Building Challenge for Unmotivated Smokers
Smoking Cessation
Primary: Time to First Quit Attempt — 0.89; 1.48 days — p=0.02
Phase 3 N=216 Maintaining Nonsmoking
Nicotine Dependence
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12 — 22; 20; 29; 20 Participants
N/A N=112 Nicotine Withdrawal Symptoms and Smoking Relapse
Nicotine Dependence
Primary: BOLD Activation in Right ACC During Parametric Flanker Task tDCS Stimulation — 1.051567464; 0.867749333; 0.8973946; 1.143702607 Percent BOLD change
Phase 4 N=179 Smoking Tobacco and Drinking Study
Smoking · Heavy Episodic Drinking
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at 3 Months — 3; 4 Participants
Phase 2 N=75 Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
Tobacco Use Disorder · Schizophrenia
Primary: Preferred Brand Smoke Intake (CO) — 3.30; 3.16; 9.07; 10.54 ppm
Phase 3 N=81 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
Tobacco Dependence
Primary: Tobacco Abstinence at 12 Weeks — 8; 5 participants
N/A N=154 Enhancing a High School Based Smoking Cessation Program
Nicotine Dependence
Primary: Abstinence Rates at the End of Treatment — 35.1; 24.3; 38.6; 36.1 percentage of participants not smoking
Phase 4 N=64 Progesterone Augmentation of Nicotine Replacement Therapy Study
Smoking Cessation
Primary: 7-day Point Prevalence of Smoking Abstinence — 8; 11; 25; 20 Participants — p=0.3253
N/A N=369 Cessation in Non-Daily Smokers
Smoking
Primary: Smoking Cessation, Continuous 6-month Abstinence — 13; 10 Participants — p=0.46
Phase 4 N=112 Smoking Cessation Treatment for Methadone Maintenance Patients
Smoking Cessation · Substance-Related Disorders
Primary: Biochemically Verified Abstinence Verified With Expired Carbon Monoxide (CO) < 8 p.p.m. — 6; 0 participants — p=0.03
Phase 2 N=129 Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women
Smoking · Nicotine Dependence
Primary: Number of Participants With Cessation Success at Week 10 After Target Quit Date — 12; 7 Participants with cessation success